| Amarjit Kumari, FNP-C | |
|
258 Foxhunt Dr, Bear, DE 19701-2536 | |
| (302) 918-7680 | |
| (302) 365-6123 |
| Full Name | Amarjit Kumari |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner - Family |
| Location | 258 Foxhunt Dr, Bear, Delaware |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1578282042 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 163W00000X | Registered Nurse | L10045857 (Delaware) | Secondary |
| 363LF0000X | Nurse Practitioner - Family | LG-0012111 (Delaware) | Primary |
| Entity Name | Precision Care & Wellness, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1285191494 PECOS PAC ID: 7214270461 Enrollment ID: O20190510000642 |
News Archive
A new psychotherapeutic ingredient, emotion regulation skills training, has been found to enhance standard cognitive behavior therapy for depression in a trial published in the current issue of Psychotherapy and Psychosomatics.
By investigating a single molecule that influences cell growth, a research group in the Purdue Cancer Center, including Brian S. Henriksen, has gained new insight into the chain of events that make some cancer cells divide uncontrollably, insight that may eventually lead to a way to break that chain, stopping cancer in its tracks. The molecule, known as Icmt, has a critical role in the development of Ras, an ordinarily beneficial protein that tells a cell to divide. The research group has determined how to inhibit Icmt's influence on Ras, without which the protein cannot develop effectively into an instigator of cell growth.
With Obama administration officials part of the campaign against the Ryan plan, other opponents also are stepping forward and launching a new wave of television ads in Wisconsin Republican Rep. Paul Ryan's very own congressional district. Meanwhile, The Washington Post analyzes some of the poll numbers behind where voters may stand on Medicare cuts.
Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that it is initiating a Phase 2 clinical study of STA-9090 in patients with advanced gastrointestinal stromal tumors (GIST). This is the sixth clinical study of STA-9090, a potent, synthetic, small molecule Hsp90 inhibitor with a novel chemical structure.
› Verified 8 days ago
| Entity Name | Precision Care And Wellness Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1912625351 PECOS PAC ID: 1951770338 Enrollment ID: O20221206002975 |
News Archive
A new psychotherapeutic ingredient, emotion regulation skills training, has been found to enhance standard cognitive behavior therapy for depression in a trial published in the current issue of Psychotherapy and Psychosomatics.
By investigating a single molecule that influences cell growth, a research group in the Purdue Cancer Center, including Brian S. Henriksen, has gained new insight into the chain of events that make some cancer cells divide uncontrollably, insight that may eventually lead to a way to break that chain, stopping cancer in its tracks. The molecule, known as Icmt, has a critical role in the development of Ras, an ordinarily beneficial protein that tells a cell to divide. The research group has determined how to inhibit Icmt's influence on Ras, without which the protein cannot develop effectively into an instigator of cell growth.
With Obama administration officials part of the campaign against the Ryan plan, other opponents also are stepping forward and launching a new wave of television ads in Wisconsin Republican Rep. Paul Ryan's very own congressional district. Meanwhile, The Washington Post analyzes some of the poll numbers behind where voters may stand on Medicare cuts.
Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that it is initiating a Phase 2 clinical study of STA-9090 in patients with advanced gastrointestinal stromal tumors (GIST). This is the sixth clinical study of STA-9090, a potent, synthetic, small molecule Hsp90 inhibitor with a novel chemical structure.
› Verified 8 days ago
| Entity Name | Apollo Health And Allied Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023891389 PECOS PAC ID: 5597110544 Enrollment ID: O20231011000144 |
News Archive
A new psychotherapeutic ingredient, emotion regulation skills training, has been found to enhance standard cognitive behavior therapy for depression in a trial published in the current issue of Psychotherapy and Psychosomatics.
By investigating a single molecule that influences cell growth, a research group in the Purdue Cancer Center, including Brian S. Henriksen, has gained new insight into the chain of events that make some cancer cells divide uncontrollably, insight that may eventually lead to a way to break that chain, stopping cancer in its tracks. The molecule, known as Icmt, has a critical role in the development of Ras, an ordinarily beneficial protein that tells a cell to divide. The research group has determined how to inhibit Icmt's influence on Ras, without which the protein cannot develop effectively into an instigator of cell growth.
With Obama administration officials part of the campaign against the Ryan plan, other opponents also are stepping forward and launching a new wave of television ads in Wisconsin Republican Rep. Paul Ryan's very own congressional district. Meanwhile, The Washington Post analyzes some of the poll numbers behind where voters may stand on Medicare cuts.
Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that it is initiating a Phase 2 clinical study of STA-9090 in patients with advanced gastrointestinal stromal tumors (GIST). This is the sixth clinical study of STA-9090, a potent, synthetic, small molecule Hsp90 inhibitor with a novel chemical structure.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Amarjit Kumari, FNP-C 207 Glendale Rd, Upper Darby, PA 19082-4017 Ph: (484) 744-0545 | Amarjit Kumari, FNP-C 258 Foxhunt Dr, Bear, DE 19701-2536 Ph: (302) 918-7680 |
News Archive
A new psychotherapeutic ingredient, emotion regulation skills training, has been found to enhance standard cognitive behavior therapy for depression in a trial published in the current issue of Psychotherapy and Psychosomatics.
By investigating a single molecule that influences cell growth, a research group in the Purdue Cancer Center, including Brian S. Henriksen, has gained new insight into the chain of events that make some cancer cells divide uncontrollably, insight that may eventually lead to a way to break that chain, stopping cancer in its tracks. The molecule, known as Icmt, has a critical role in the development of Ras, an ordinarily beneficial protein that tells a cell to divide. The research group has determined how to inhibit Icmt's influence on Ras, without which the protein cannot develop effectively into an instigator of cell growth.
With Obama administration officials part of the campaign against the Ryan plan, other opponents also are stepping forward and launching a new wave of television ads in Wisconsin Republican Rep. Paul Ryan's very own congressional district. Meanwhile, The Washington Post analyzes some of the poll numbers behind where voters may stand on Medicare cuts.
Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that it is initiating a Phase 2 clinical study of STA-9090 in patients with advanced gastrointestinal stromal tumors (GIST). This is the sixth clinical study of STA-9090, a potent, synthetic, small molecule Hsp90 inhibitor with a novel chemical structure.
› Verified 8 days ago
Ms. Amanda Jennifer Bostick, FNP-C Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 121 Becks Woods Dr Ste 100, Bear, DE 19701 Phone: 302-261-5600 Fax: 302-836-4302 | |
Sarah Grove, FNP-C Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 404 Fox Hunt Dr, Bear, DE 19701 Phone: 302-652-2455 Fax: 302-322-6251 | |
Deborah F Bryant, FNP-BC Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 404 Fox Hunt Dr, Fox Run Shopping Center, Bear, DE 19701 Phone: 302-836-2864 Fax: 302-918-3219 | |
Justine Kiyang, Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 193 Portside Ct, Bear, DE 19701 Phone: 302-333-1648 | |
Miss Leslie Yvette Sterling, FNP-BC Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 53 Perth St, Bear, DE 19701 Phone: 267-456-9391 | |
Anita K Kombo, FNP-C Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1545 Pulaski Hwy, Bear, DE 19701 Phone: 302-832-8701 | |
Vinneta Shorter, NP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 121 Becks Woods Dr Ste 200, Bear, DE 19701 Phone: 302-834-7676 |